Treatment continuation in patients receiving biological agents or conventional DMARD therapy
Open Access
- 1 September 2005
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 64 (9), 1274-1279
- https://doi.org/10.1136/ard.2004.031476
Abstract
Objective: To compare drug continuation rates in patients with rheumatoid arthritis who start on a biological agent and in a control group of patients with a change in disease modifying antirheumatic drug (DMARD) treatment after previous DMARD failure. Methods: Patients with rheumatoid arthritis enrolled in the German biologics register between May 2001 and September 2003 were included in the study. Data were available for 511 patients treated with etanercept, 343 with infliximab, 70 with anakinra, and 599 controls. Propensity scores were used to select a subsample of patients from the control group who were likely to be treated with biological agents because of their disease severity, as well as comparable infliximab and etanercept cases. Results: Treatment continuation after 12 months was similar for etanercept (68.6% (95% confidence interval, 62% to 75%)) and infliximab (65.4% (58% to 73%)) but lower for anakinra (59% (41% to 77%)). Treatment continuation was more likely for patients on combinations of biological agents and DMARDs than for those on infliximab or etanercept alone. Patients treated with biological agents were more severely ill than those in the control group and had more previous DMARD failures. After adjustment for baseline differences, the continuation rates were higher in patients treated with biological agents than in comparable control patients treated with leflunomide or leflunomide/methotrexate. Conclusions: Treatment continuation of biological agents in clinical practice is less likely than in randomised clinical trials but more likely than in comparable controls treated with conventional DMARDs.This publication has 14 references indexed in Scilit:
- Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2003
- Concomitant Leflunomide Therapy in Patients with Active Rheumatoid Arthritis despite Stable Doses of MethotrexateAnnals of Internal Medicine, 2002
- Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern SwedenAnnals Of The Rheumatic Diseases, 2002
- Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomesArthritis & Rheumatism, 2002
- Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin‐1 receptor antagonist, in combination with methotrexate: Results of a twenty‐four–week, multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Etanercept Therapy in Rheumatoid ArthritisAnnals of Internal Medicine, 1999
- Vergleichende Evaluation einer deutschen Version des Health Assessment Questionnaires (HAQ) und des Funktionsfragebogens Hannover (FFbH) (Comparative evaluation of a German version of the Health Assessment Questionnaire (HAQ) and the Hannover Functional Ability Questionnaire (HFAQ))Zeitschrift für Rheumatologie, 1997
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995